研究分担者： 杉浦　亙　（(独)国立病院機構名古屋医療センター）

研究協力者： 吉田　　繁　（北海道大学）
　　　　　　潟永　博之　（国立国際医療研究センター）
　　　　　　鯉渕　智彦　（東京大学医学部医科学研究所）
　　　　　　加藤　真吾　（慶応大学）
　　　　　　渡辺　　大　（国立病院機構大阪医療センター）
　　　　　　西澤　雅子　（国立感染症研究所）
　　　　　　蜂谷　敦子　（国立病院機構名古屋医療センター）
　　　　　　服部　純子　（DRP/NCI）
　　　　　　松下　修三　（熊本大学エイズ学研究センター）
　　　　　　宮崎菜穂子　（国立感染症研究所、東京大学医科学研究所）
　　　　　　横幕　能行　（国立病院機構名古屋医療センター）
　　　　　　和山　行正　（北里大塚バイオメディカルアッセイ研究所）
　　　　　　橋本　　修　（三菱化学メディエンス）

研究分担者： 吉野　宗宏　（国立病院機構大阪医療センター薬剤科)

研究協力者： 和泉啓司郎　（国立国際医療研究センター）
　　　　　　千田　昌之　（国立国際医療研究センター）
　　　　　　増田　純一　（国立国際医療研究センター）
　　　　　　酒井　真依　（国立国際医療研究センター）
　　　　　　植田　孝介　（北海道大学病院）
　　　　　　浅野　逸郎　（北海道大学病院）
　　　　　　國本　雄介　（札幌医科大学付属病院）
　　　　　　井上　正朝　（旭川医科大学病院）
　　　　　　佐藤　麻希　（国立病院機構仙台医療センター）
　　　　　　山田　徹　　（新潟市民病院）
　　　　　　斎藤　直美　（新潟大学医歯学総合病院）
　　　　　　丸山　一郎　（新潟県立新発田病院）
　　　　　　下川千賀子　（石川県立中央病院）
　　　　　　杉浦　互　　（国立病院機構名古屋医療センター）
　　　　　　柴田　雅章　（国立病院機構名古屋医療センター）
　　　　　　畝井　浩子　（広島大学病院）
　　　　　　濱本　京子　（広島大学病院）
　　　　　　藤田　啓子　（広島大学病院）
　　　　　　藤井　健司　（広島大学病院）
　　　　　　松本　俊治　（広島市立広島市民病院）
　　　　　　開　　浩一　（広島市立広島市民病院）
　　　　　　井上　千鶴　（広島県立広島病院）
　　　　　　大石　裕樹　（国立病院機構九州医療センター）
　　　　　　嶺　　豊春　（長崎大学医学部・歯学部附属病院）
　　　　　　新江　裕貴　（琉球大学医学部附属病院）
　　　　　　日笠　真一　（兵庫医科大学病院）
　　　　　　冨島　公介　（国立病院機構姫路医療センター）
　　　　　　石樋　康浩　（大阪府立急性期・総合医療センター）
　　　　　　治田　匡平　（奈良県立医科大学附属病院）
　　　　　　市田　裕之　（大阪市立総合医療センター）
　　　　　　矢倉　裕輝　（国立病院機構大阪医療センター）
　　　　　　櫛田　宏幸　（国立病院機構大阪医療センター）

研究成果の刊行に関する一覧

Nishijima T, Takano M, Ishisaka M, Komastu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mistuya H, and Oka S on behalf of the Epzicom-Truvada study team.
Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for treatment naive Japanese Patients with HIV-1 Infection: a randomized multicenter trial.
Intern Med. 52: 735-744, 2013.

Gatanaga H, Hayashida T, Tanuma J, and Oka S.
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Clin Infect Dis. 56 (12): 1812-1819, 2013.

Hamada Y, Nagata N, Shimbo T, Igari T, Nakashima R, Asayama N, Nishimura S, Yazaki H, Teruya K, Gatanaga H, Kikuchi Y, Akiyama J, Ohmagari N, Uemura N and Oka S.
Assessment of the antigenemia assay for the diagnosis of cytomegalovirus gastrointestinal diseases in HIV-infected patients.
AIDS Patient Care STDs. 27 (7): 387-391, 2013.

Tanuma J, Sano K, Teruya K, Watanabe K, Aoki T, Honda H, YazakiH, Tsukada K, Gatanaga H, Kikuchi Y, and Oka S.
Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.
PLOS One. 8 (8): e70611, 2013.

Mizushima D, Nishijima T, Gatanaga H, Tsukada K, Teruya K, Kikuchi Y, Oka S.
Preemptive therapy prevents cytomegalovirus end-organ disease in treatment-naïve patients with advanced HIV-1 Infection in the HAART era.
PLOS One. 8 (5): e65348, 2013.

Tsuchiya K, Ode H, Hayashida T, Kakizawa J, Sato H, Oka S, and Gatanaga H.
Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism.
Scientific Report. 3: 2389, 2013.

Gatanaga H, Murakoshi H, Hachiya A, Hayashida T, Ode H, Sugiura W, Takiguchi M, and Oka S.
Naturally Selected Rilpivirine-Resistant HIV-1 Variants by Host Cellular Immunity.
Clin Infect Dis. 57 (7): 1051-1055, 2013.

Hamada Y, Nishijima T, Watanabe K, Komatsu H, Teruya K, Gatanaga H, Kikuchi Y, and Oka S.
Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
PLOS One. 8 (7): e69845, 2013.

Nishijima T, Gatanaga H, Komatsu H, Takano M, Ogane M, Ikeda K, and Oka S.
Illicit drug use is a significant risk factor for loss to follow up in patients with HIV-1 infection at a large urban HIV clinic in Tokyo.
PLOS One. 8 (8): e72310, 2013.

Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Ishisaka M, Tsukada K, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, and Oka S on behalf of the SPARE study team.
Switching Tenofovir/Emtricitabine plus Lopinavir/r to Raltegravir plus Darunavir/r in Patients with Suppressed Viral Load Did Not Result in Improvement of Renal Function but Could Sustain Viral Suppression: A Randomized Multicenter Trial.
PLOS One. 8 (8): e73639, 2013.

Watanabe K, Murakoshi H, Tamura Y, Koyanagi M, Chikata T, <u>Gatanaga H</u>, <u>Oka S</u>, and Takiguchi M.
Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides.
Microb Infect. 15: 874-886, 2013.

Nishijima T, <u>Gatanaga H</u>, Komatsu H, Takano M, Ogane M, Ikeda K, and <u>Oka S</u>.
High prevalence of illicit drug use in men who have sex with men with HIV-1 infection in Japan.
PLOS One. 8 (12): e81960, 2013.

Mizushima D, Tanuma J, Kanaya F, Watanabe K, Nishijima T, <u>Gatanaga H</u>, Lam NT, Dung NTH, Kinh NV, and <u>Oka S</u>.
WHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.
PLOS One. 8 (11): e79885, 2013.

Nishijima T, Hamada Y, Watanabe K, Komatsu H, Kinai E, Tsukada K, Teruya K, <u>Gatanaga H</u>, Kikuchi Y, and <u>Oka S</u>.
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
PLOS One. 8 (10): e77268, 2013.

Nishijima T, Shimbo T, Komastu H, Hamada Y, Gatanaga H, and <u>Oka S</u>.
Incidence and risk factors for incident hepatitis C infection among men who have sex with men with HIV-1 infection in a large urban HIV clinic in Tokyo.
JAIDS (Brief Report). 65 (2): 213-217, 2014.

Nishijima T, Gatanaga H, and <u>Oka S</u>.
Traditional but not HIV-related factors are associated with nonalcoholic fatty liver disease in Asian patients with HIV-1 infection.
PLOS One. 9 (1): e87596, 2014.

Hamada Y, Nagata N, Nishijima T, Shinbo T, Asayama N, Kishida Y, Sekine K, Tanaka S, Aoki T, Watanabe K, Akiyama J, Igari T, Mizokami M, Uemura N, and <u>Oka S</u>.
Impact of HIV Infection on Colorectal Tumors: A Prospective Colonoscopic Study of Asian Patients.
JAIDS. 65 (3): 312-317, 2014.

Matsunaga A, Hishima T, Tanaka N, Yamazaki M, Mochizuki M, Tanuma J, <u>Oka S</u>, Ishizaka Y, Shimura M and Hagiwara S.
DNA methylation profiling can classify HIV-associated lymphomas.
AIDS. 28(4): 503-510, 2014.

Suzuki Y, Tachikawa N, Gatanaga H, and <u>Oka S</u>.
Slow turnover of HIV-1 receptors on quiescent CD4$^+$ T cells causes prolonged surface retention of gp120 immune complexes *in vivo.*
PLOS One. 9 (2): e86479, 2014.

Watanabe K, Aoki T, Nagata N, Tanuma J, Kikuchi Y, <u>Oka S</u> and Gatanaga H.
Clinical significance of high anti-Entamoeba histolytica antibody titer in asymptomatic HIV-1-infected individuals.
J Infect Dis. Dec 13. [Epub ahead of print], 2013.

Nishijima T, Shimbo T, Komatsu H, Hamada Y, Gatanaga H, and <u>Oka S</u>.
Cumulative exposure of ritonavir-boosted atazanavir is associated with cholelithiasis formation in patients with HIV-1 infection.
J Antimicrob Chemothera. Dec 29. [Epub ahead of print], 2013.

Kinai E, Nishijima T, Mizushima D, Watanabe K, Aoki T, Honda H, Yazaki H, Genka I, Tanuma J, Teruya K, Tsukada K, Gatanaga H, Kikuchi Y, and Oka S.
Prevalence and risk factors of bone mineral density abnormalities in Japanese HIV-infected patients.
AIDS Res Hum Retrovirol. in press.

Shibata M, Takahashi M, Yoshino M, Kuwahara T, Nomura T, Yokomaku Y, Sugiura W.
Development and application of a simple LC-MS method for the determination of plasma rilpivirine (TMC-278) concentrations.
The journal of medical investigation. 60(1-2): 35-40, 2013.

Katano H, Yokomaku Y, Fukumoto H, Kanno T, Nakayama T, Shingae A, Sugiura W, Ichikawa S, Yasuoka A.
Seroprevalence of Kaposi's sarcoma-associated herpesvirus among men who have sex with men in Japan.
Journal of medical virology. 85(6): 1046-1052, 2013.

Iijima K, Okudaira N, Tamura M, Doi A, Saito Y, Shimura M, Goto M, Matsunaga A, Kawamura YI, Otsubo T, Dohi T, Hoshino S, Kano S, Hagiwara S, Tanuma J, Gatanaga H, Baba M, Iguchi T, Yanagita M, Oka S, Okamura T, Ishizaka Y.
Viral protein R of human immunodeficiency virus type-1 induces retrotransposition of long interspersed element-1.
Retrovirology. 10: 83, 2013.

Motozono C, Miles JJ, Hasan Z, Gatanaga H, Meribe SC, Price DA, Oka S, Sewell AK, Ueno T.
CD8[+] T cell cross-reactivity profiles and HIV-1 immune escape towards an HLA-B35-restricted immunodominant Nef epitope.
PLoS One. 8(6): e66152, 2013.

Nishijima T, Komatsu H, Teruya K, Tanuma J, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100000copies/ml.
AIDS. 27(5): 839-42, 2013.

Yanagisawa K, Tanuma J, Hagiwara S, Gatanaga H, Kikuchi Y, Oka S.
Epstein-Barr viral load in cerebrospinal fluid as a diagnostic marker of central nervous system involvement of AIDS-related lymphoma.
Intern Med. 52(9): 955-9, 2013.

Shindo T, Nishijima T, Teruya K, Mizushima D, Gatanaga H, Oka S.
Combination of high-dose dexamethasone and antiretroviral therapy rapidly improved and induced long-term remission of HIV-related thrombocytopenic purpura.
J Infect Chemother. 19(6): 1170-2, 2013.

Lee JH, Hachiya A, Shin SK, Lee J, Gatanaga H, Oka S, Kirby KA, Ong YT, Sarafianos SG, Folk WR, Yoo W, Hong SP, Kim SO.
Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.
Clin Microbiol Infect. 19(6): E263-70, 2013.

Nishijima T, Shimbo T, Komatsu H, Takano M, Tanuma J, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.
Urinary beta-2 microglobulin and alpha-1 microglobulin are useful screening markers for tenofovir-induced kidney tubulopathy in patients with HIV-1 infection: a diagnostic accuracy study.
J Infect Chemother. 19(5): 850-7, 2013.

Hamada Y, Nagata N, Honda H, Teruya K, <u>Gatanaga H</u>, Kikuchi K, Oka S.
Idiopathic oropharyngeal and esophageal ulcers related to HIV infection successfully treated with antiretroviral therapy alone.
Intern Med. 52(3): 393-395, 2013.

Yagita Y, Kuse N, Kuroki K, <u>Gatanaga H</u>, Carlson JM, Chikata T, Brumme ZL, Murakoshi H, Akahoshi T, Pfeifer N, Mallal S, John M, Ose T, Matsubara H, Kanda R, Fukunaga Y, Honda K, Kawashima Y, Ariumi Y, Oka S, Maenaka K, Takiguchi M.
Distinct HIV-1 escape patterns selected by cytotoxic T cells with identical epitope specificity.
J Virol. 87(4): 2253-63, 2013.

Ayumi Kudoh, Shoukichi Takahama, Tatsuya Sawasaki, Hirotaka Ode, Masaru Yokoyama, Akiko Okayama, Akiyo Ishikawa, Kei Miyakawa, Satoko Matsunaga, Hirokazu Kimura, <u>Wataru Sugiura</u>, Hironori Sato, Hisashi Hirano, Shigeo Ohno, Naoki Yamamoto and Akihide Ryo.
The phosphorylation of HIV-1 Gag by atypical protein kinase C facilitates viral infectivity by promoting Vpr incorporation into virions.
Retrovirology. 11(1): 9, 2014.

Nishizawa M, Hattori J, Shiino T, Matano T, Heneine W, Johnson JA, <u>Sugiura W</u>.
Highly-Sensitive Allele-Specific PCR Testing Identifies a Greater Prevalence of Transmitted HIV Drug Resistance in Japan.
PLoS One. 8(12): e83150, 2013.

Saito A, Nomaguchi M, Kono K, Iwatani Y, Yokoyama M, Yasutomi Y, Sato H, Shioda T, <u>Sugiura W</u>, Matano T, Adachi A, Nakayama EE, Akari H.
TRIM5 genotypes in cynomolgus monkeys primarily influence inter-individual diversity in susceptibility to monkey-tropic human immunodeficiency virus type 1.
The Journal of general virology. 94(Pt 6): 1318-1324, 2013.

Nii-Trebi NI, Ibe S, Barnor JS, Ishikawa K, Brandful JA, Ofori SB, Yamaoka S, Ampofo WK, <u>Sugiura W</u>.
HIV-1 Drug-Resistance Surveillance among Treatment-Experienced and -Naive Patients after the Implementation of Antiretroviral Therapy in Ghana.
PloS one. 8(8): e71972, 2013.

Jahanbakhsh F, Ibe S, Hattori J, Monavari SH, Matsuda M, Maejima M, Iwatani Y, Memarnejadian A, Keyvani H, Azadmanesh K, <u>Sugiura W</u>.
Molecular epidemiology of HIV type 1 infection in Iran: genomic evidence of CRF35_AD predominance and CRF01_AE infection among individuals associated with injection drug use.
AIDS research and human retroviruses. 29(1): 198-203, 2013.

ahanbakhsh F, Hattori J, Matsuda M, Ibe S, Monavari SH, Memarnejadian A, Aghasadeghi MR, Mostafavi E, Mohraz M, Jabbari H, Kamali K, Keyvani H, Azadmanesh K, <u>Sugiura W</u>.
Prevalence of transmitted HIV drug resistance in Iran between 2010 and 2011.
PloS one. 8(4): e61864, 2013.

<u>豊嶋崇徳</u>
「HIV 感染症診断・治療・看護マニュアル　改訂第 9 版」（平成 25 年 10 月刊行）
編集：北海道大学病院 HIV 感染症対策委員会

<u>豊嶋崇徳</u>
「平成 25 年度北海道 HIV/AIDS 医療者研修会記録集」（平成 25 年 9 月刊行）
編集：北海道大学病院 HIV 感染症対策委員会

福山由美，市川誠一，大林由美子，<u>杉浦亙</u>，<u>横幕能行</u>.
愛知県におけるエイズ診療拠点病院初診患者の受診遅れと検査遅れに関連する要因.
日本エイズ学会誌.　15(2): 119-127, 2013.

平野淳，高橋昌明，柴田雅章，野村敏治，横幕能行，杉浦亙.
結核を合併した日本人 HIV 感染症例に対するラルテグラビルカリウムとリファンピシン併用に関する検討.
日本エイズ学会誌. 15(1): 36-39, 2013.

辻明宏，大郷剛，福井重文，米本仁史，上平朝子，中西宣文.
内服薬剤療法に抵抗性でエプロステノール静注療法が効果的であったHIV関連肺動脈性肺高血圧症の1例.
Therapeutic Research. 34(9): 1176-1178, 2013.

木村哲，山本政弘，橋野聡，伊藤俊弘，上平朝子.
HIV 感染症の検査・診断・治療における「連携」の諸問題について考える．座談会
医薬の門．第 53 巻 第 6 号：357-365 2013 年 8 月.

上平朝子
結核治療中に発症した急性 C 型肝炎.
HIV 感染症と AIDS の治療．VOL.4 No.2, P39-41, メディカルレビュー社．2013 年 11 月.

須貝恵，鈴木智子，センテノ田村恵子，辻典子，井内亜紀子，濱本京子，吉用緑，山本政弘.
活用状況を考慮した「拠点病院診療案内」のあり方についての検討－拠点病院診療案内の活用に関するアンケート調査より－.
日本エイズ学会雑誌. 15(3): 199-200, 2013.

須貝恵，辻典子，吉用緑，センテノ田村恵子，鈴木智子，井内亜紀子，濱本京子，山本政弘.
拠点病院の患者紹介現状から考える医療体制の課題－拠点病院から拠点病院以外の医療機関への患者紹介実績調査より－.
日本エイズ学会雑誌. 15(3): 201-203, 2013.

前田憲昭，溝部潤子，吉川博政，大西正和，北田卯美，中川裕美子，藤倉弓子，能島初美，宮浦朗子.
歯科診療に必要なバリアーテクニック教本.
HIV 感染症の医療体制整備に関する研究班．30, 2014 年.

田中千枝子
1 章 現場研究と質的研究法
社会福祉・介護福祉の質的研究法　実践者のための現場研究. pp.002-007, 中央法規出版，2013 年.

吉野宗宏
HIV 感染症.
感染症薬物療法トレーニングブック．182-192, 2013 年.

研究成果の別刷

INTERNAL🔬MEDICINE

Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients with HIV-1 Infection: A Randomized Multicenter Trial

Takeshi Nishijima[1,2], Misao Takano[1], Michiyo Ishisaka[1], Hirokazu Komatsu[3],
Hiroyuki Gatanaga[1,2], Yoshimi Kikuchi[1], Tomoyuki Endo[4], Masahide Horiba[5],
Satoru Kaneda[6], Hideki Uchiumi[7], Tomohiko Koibuchi[8], Toshio Naito[9], Masaki Yoshida[10],
Natsuo Tachikawa[11], Mikio Ueda[12], Yoshiyuki Yokomaku[13], Teruhisa Fujii[14],
Satoshi Higasa[15], Kiyonori Takada[16], Masahiro Yamamoto[17], Shuzo Matsushita[2],
Masao Tateyama[18], Yoshinari Tanabe[19], Hiroaki Mitsuya[20,21], Shinichi Oka[1,2],
on behalf of the Epzicom-Truvada study team

Abstract

Objective To compare the efficacy and safety of fixed-dose abacavir/lamivudine (ABC/3TC) and tenofovir/emtricitabine (TDF/FTC) with ritonavir-boosted atazanavir (ATV/r) in treatment-naïve Japanese patients with HIV-1 infection.

Methods A 96-week multicenter, randomized, open-label, parallel group pilot study was conducted. The endpoints were times to virologic failure, safety event and regimen modification.

Results 109 patients were enrolled and randomly allocated (54 patients received ABC/3TC and 55 patients received TDF/FTC). All randomized subjects were analyzed. The time to virologic failure was not significantly different between the two arms by 96 weeks (HR, 2.09; 95% CI, 0.72-6.13; p=0.178). Both regimens showed favorable viral efficacy, as in the intention-to-treat population, 72.2% (ABC/3TC) and 78.2% (TDF/FTC) of the patients had an HIV-1 viral load <50 copies/mL at 96 weeks. The time to the first grade 3 or 4 adverse event and the time to the first regimen modification were not significantly different between the two arms (adverse event: HR 0.66; 95% CI, 0.25-1.75, p=0.407) (regimen modification: HR 1.03; 95% CI, 0.33-3.19, p=0.964). Both regimens were also well-tolerated, as only 11.1% (ABC/3TC) and 10.9% (TDF/FTC) of the patients discontinued the allocated regimen by 96 weeks. Clinically suspected abacavir-associated hypersensitivity reactions occurred in only one (1.9%) patient in the ABC/3TC arm.

Conclusion Although insufficiently powered to show non-inferiority of viral efficacy of ABC/3TC relative to TDF/FTC, this pilot trial suggested that ABC/3TC with ATV/r is a safe and efficacious initial regimen for HLA-B*5701-negative patients, such as the Japanese population.

Introduction

The fixed-dose combinations of tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg and abacavir sulfate 600 mg/lamivudine 300 mg are components of antiretroviral therapy for treatment-naïve patients with HIV-1 infection in developed countries (1, 2). The efficacy and safety of tenofovir/emtricitabine (TDF/FTC) and abacavir/lamivudine (ABC/3TC) remain the focus of ongoing debate. The ACTG 5202 trial demonstrated that the viral efficacy of ABC/3TC is inferior to that of TDF/FTC among treatment-naïve patients with a baseline HIV viral load of >100,000 copies/mL receiving efavirenz or ritonavir-boosted atazanavir as a key drug (3). On the other hand, the HEAT study showed that the viral efficacy of ABC/3TC is not inferior to that of TDF/FTC, regardless of the baseline viral load when used in combination with lopinavir/ritonavir (4).

With regard to safety, the occurrence of ABC-associated serious hypersensitivity reactions, the most important adverse effect of ABC affecting 5-8% of patients, has limited its use (5). However, screening for HLA-B*5701 or prescribing ABC in HLA-B*5701-negative populations, such as the Japanese, can reduce the incidence of immunologically-confirmed hypersensitivity to 0% (6, 7). Another negative aspect of ABC use is its association with myocardial infarction, as reported by the D:A:D study (8). However, the possible association of myocardial infarction with ABC was not confirmed by a recent meta-analysis report of the US Food and Drug Administration (9). On the other hand, renal proximal tubular damage leading to renal dysfunction and a loss of phosphate, which can result in decreased bone mineral density, is a well-known adverse effect of TDF (10-14).

Taking this background into account, the American Department of Health and Human Services (DHHS) Guidelines place TDF/FTC as the preferred drug and ABC/3TC as an alternative choice, whereas other international guidelines, including the European AIDS Clinical Society (EACS) Guidelines and the Japanese Guidelines, recommend both TDF/FTC and ABC/3TC as preferred choices (1, 2, 15).

Randomized control trials comparing TDF/FTC and ABC/3TC have been conducted in the US and Europe, but not in other parts of the world (4, 16, 17). The efficacy and safety of these two fixed-dose regimens in patients with different genetic backgrounds and body statures might not be similar to the results of previous trials, especially considering that the prevalence of HLA-B*5701 is zero in the Japanese population (7). Moreover, the degree of decrement in the renal function with TDF is larger in patients with a low body weight, such as the Japanese, which might limit the use of TDF in patients with a high risk for renal dysfunction (18-20).

Based on the above described background, the present randomized trial was originally designed in 2007 to elucidate whether the viral efficacy of ABC/3TC is not inferior to that of TDF/FTC with ritonavir-(100 mg) boosted atazanavir (300 mg) in treatment-naïve Japanese patients, whose body weight is much lower than Whites or Blacks (21). However, the independent data and safety monitoring board (DSMB) recommended that the protocol be modified to examine the efficacy, safety and tolerability among Japanese patients with HIV-1 infection for 96 weeks as a pilot trial because only 109 patients were enrolled and randomized at the end of the enrollment period despite a planned sample size of 240 patients, primarily due to the above mentioned negative reports of ABC use in the D:A:D study and ACTG 5202 (3, 8).

Materials and Methods

This clinical trial was designed and reported according to the recommendations of the Consolidated Standard of Reporting Trials (CONSORT) statement (22). The protocol and supporting CONSORT checklist are available as supplementary files (see Supplementary files 1 and 2).

Ethics statement

The Research Ethics Committee of each participating center approved the study protocol. All patients enrolled in this study provided a written informed consent. This study was conducted according to the principles expressed in the Declaration of Helsinki.

Study design

The Epzicom-Truvada study is a phase 4, multicenter, randomized, open-label, parallel group pilot study conducted in Japan that compared the efficacy and safety of a fixed dose of ABC/3TC and TDF/FTC, both combined with ritonavir-boosted atazanavir (ATV/r) for the initial treatment of HIV-1 infection for 96 weeks. Enrollment of patients began in November 2007 and ended in March 2010, and the follow-up period ended in February 2012. With a one to one ratio, the patients were randomly assigned to receive either a fixed dose of ABC/3TC or TDF/FTC, both administered with ATV/r. The randomization was stratified according to each participating site and conducted at the data center with

independent clinical research coordinators using a computer-generated randomization list prepared by a statistician with no clinical involvement in the trial.

Study patients

This study population included treatment-naïve Japanese patients aged 20 or over with HIV-1 infection who met the eligibility criteria for the commencement of antiretroviral therapy according to the DHHS Guidelines in place in the U.S. at the time of the writing of the study protocol (a CD4 count <350/μL or a history of AIDS-defining illness regardless of the CD4 count) (23). Patients were screened and excluded if they had previously taken lamivudine, tested positive for hepatitis B surface antigens, had comorbidities such as hemophilia or diabetes mellitus that required medical treatment, congestive heart failure or cardiac myopathy or if they were considered not suitable for enrollment by the attending physicians. Candidates were also excluded if their alanine aminotransferase level was 2.5 times greater than the upper limit of normal, they had an estimated glomerular filtration rate (eGFR) calculated using the Cockcroft-Gault equation of <60 mL/min, {creatinine clearance = [(140- age) × weight (kg)]/(serum creatinine ×72)(×0.85 for females)} or a serum phosphate level <2 mg/dL or had active opportunistic diseases that required treatment (24). Each patient's actual body weight was used for the calculation of eGFR. At screening, a genotypic drug resistant test and screening for the HLA-B*5701 allele were permitted but not required because the prevalence of both the drug resistant virus and the HLA-B*5701 allele are low in Japanese patients (7, 25). Medical history, including a history of AIDS-defining illnesses and other comorbidities, was also collected. Enrollment stopped on March 3, 2008 due to the recommendation from the DSMB of the trial based on the interim analysis of the ACTG5202 that ABC/3TC is less effective than TDF/FTC in patients with a baseline viral load >100,000 copies/mL (3). Accordingly, the DSMB recommended that the trial should be restarted with modified inclusion criteria: to enroll patients with an HIV-1 viral load of <100,000 copies/mL at screening, and the enrollment restarted from April 1, 2008.

Study procedures

Required visits for participants for clinical and laboratory assessments were at screening, enrollment and every 4 weeks until the viral load diminished to <50 copies/mL. For patients with a viral load <50 copies/mL, the required visit interval was every 12 weeks for the duration of the study. The evaluation performed at each visit included a physical examination, CD4 cell count, HIV-1 RNA viral load, a complete blood cell count and blood chemistries (total bilirubin, alanine aminotransferase, lactate dehydrogenase, serum creatinine, potassium, phosphate, triglycerides and low-density lipoprotein (LDL) cholesterol) and a urine examination of the levels of phosphate, creatinine and β2 microglobulin. The values of urinary β2 microglobulin were expressed relative to a urinary creatinine level of 1 g/L (/g Cr). The per-

cent tubular resorption of phosphate was calculated using the following formula: {1-[(urine phosphate × serum creatinine)/(urine creatinine × serum phosphate)]} ×100 (26). All data, including the HIV-1 RNA viral load, were collected at each participating site and sent to the data center. Grade 3 or 4 serious adverse events were reported to the DSMB, which made a judgment whether they were caused by the study drugs. Independent research coordinators at the data center visited at least 10 facilities every year to monitor the accuracy of the submitted data and compliance to the study protocol. All authors vouch for the completeness and accuracy of the reported data.

Statistical analysis

The sample size calculation was originally conducted as follows: Assuming a 90% success rate in the TDF/FTC arm at week 48, a sample size of 224 patients (112 patients per arm) provided 80% power (one sided, α=0.05) to establish non-inferiority of ABC/3TC to TDF/FTC each in combination with ATV/r. Non-inferiority was defined as the lower bound of the two-sided 95% confidence interval (CI) with the treatment difference being above -10%. Based on this assumption, the targeted sample size was set to 240 patients (120 in each arm). However, as previously described, due to the shortage of accrued subjects, this study was underpowered and conducted as a pilot trial.

The primary efficacy endpoint was the time from randomization to virologic failure (defined as a confirmed HIV-1 RNA >1,000 copies/mL at or after 16 weeks and before 24 weeks or >200 copies/mL at or after 24 weeks) (3). The secondary efficacy endpoints included the time from randomization to either virologic failure or ART modification and a comparison of the proportions of patients with HIV-1 RNA <50 copies/mL at weeks 48 and 96 regardless of previous virologic failure. The intent-to-treat (ITT) population comprising all randomized subjects was used to assess the efficacy data; however, a comparison of the proportion of virologically-suppressed patients was conducted with both the ITT and a per protocol population while on the initial randomized regimen.

The safety endpoint was the time from randomization to the first occurrence of grade 3 or 4 laboratory data or abnormal symptoms that were at least one grade higher than the baseline. Isolated hyperbilirubinemia was excluded from the safety endpoints. The grade of adverse events was classified according to the Division of AIDS Table for grading the severity of adult and pediatric events, version 2004 (27). The tolerability endpoint was the time from randomization to any regimen modification. The safety and tolerability endpoints were calculated in the ITT population. Changes per protocol in the CD4 cell count, lipid markers and renal tubular markers at weeks 48 and 96 were compared using the Mann-Whitney test. A repeated measures mixed model was used to estimate and compare changes in the renal function between the two arms (17). The renal function was calculated using the Modification of Diet in Renal Disease study

Figure 1.   Enrollment, randomization and disposition of patients.

Table 1.   Demographic and Baseline Characteristics

	ABC/3TC (n=54)	TDF/FTC (n=55)	Total (n=109)
Sex (male), n (%)	53 (98.1)	54 (98.2)	107 (98.2)
Age (years)[†]	39 (28.8-44)	35 (29-42)	36 (29-42.5)
CD4 count (/μL)[†]	236.5 (194-301.3)	269 (177-306)	257 (194-305)
HIV RNA viral load ($\log_{10}$/mL)[†]	4.29 (3.92-4.67)	4.28 (3.86-4.60)	4.28 (3.89-4.67)
HIV RNA viral load >100,000 $\log_{10}$/mL, n (%)	1 (1.9)	0 (0)	1 (0.9%)
Route of transmission (homosexual contact), n (%)	47 (87)	49 (89.1)	96 (88.1)
History of AIDS n (%)	1 (1.9)	5 (9.1)	6 (5.5)
Body weight (kg)[†]	64 (59-72.1)	63.1 (58-69)	64 (58.3-70.7)
Body mass index (kg/m^2)[†]	22.6 (20.4-24.2)	21.9 (20.3-23.6)	22.4 (20.3-23.7)
eGFR (mL/min/1.73 m^2)[†]	96.9 (82.7-107.3)	94.4 (83.6-105.7)	96.7 (83.0-106.7)
Creatinine clearance (mL/min)[†]	119.3 (105.4-136.6)	124.6 (103-139.3)	120.3 (104.7-138.3)
Serum creatinine (mg/dL)[†]	0.76 (0.67-0.83)	0.75 (0.68-0.84)	0.76 (0.68-0.83)
Urinary β2 microglobulin (μg/g Cre)[†]	195.8 (98.3-505.3)	138.4 (86.8-426.4)	172.9 (88.3-458.7)
Tubular resorption of phosphate (%)[†]	92.9 (90-95.1)	92.3 (87.7-95.2)	92.7 (89.3-95.1)
LDL-cholesterol (mg/dL)[†]	91.5 (75-125.5)	94 (72.5-111.5)	94 (74.5-114)
Triglycerides (mg/dL)[†]	132 (98-170.5)	114 (73-184)	127 (85.5-175)
Hypertension, n (%)	3 (5.6)	1 (1.8)	4 (3.7)
Diabetes mellitus, n (%)	0 (0)	0 (0)	0 (0)
Concurrent use of nephrotoxic drugs, n (%)	10 (18.5)	10 (18.2)	20 (18.3)
Hepatitis C, n (%)	0 (0)	0 (0)	0 (0)

[†]median (interquartile range)

IQR: interquartile range, AIDS: acquired immunodeficiency syndrome, eGFR: estimated glomerular filtration rate, LDL: low-density lipoprotein

equation adjusted for the Japanese population (28), and a sensitivity analysis was conducted using the above mentioned Cockcroft-Gault equation.

Time-to-event distributions were estimated using the Kaplan-Meier method and compared using the two-sided log-rank test. Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated using the Cox proportional hazards model. For grade 3 or 4 serious adverse events caused by the study drugs, the description and severities were recorded. Statistical significance was defined at two-sided p values <0.05. All statistical analyses were performed with The Statistical Package for Social Sciences ver. 17.0 (SPSS, Chicago, IL).

Results

Patient disposition and baseline characteristics

109 patients from 18 centers were enrolled and randomized between November 2007 and March 2010. Of these patients, 54 and 55 were allocated to the ABC/3TC and TDF/FTC arms, respectively (Fig. 1). The baseline demographics and characteristics are shown in Table 1. Most patients were men, with a median body weight of 64 kg. The median CD4 cell count was 257/μL (IQR: 194-305). One patient in the ABC/3TC arm had a baseline HIV-1 RNA level of >100,000

Figure 2. Efficacy results over 96 weeks. (A) Time to protocol-defined virologic failure. (B) Time to the first occurrence of either virologic failure or discontinuation of the initially randomized regimen. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine


Figure 3. Efficacy results at 48 and 96 weeks. Proportion of patients with an HIV RNA level <50 copies/mL regardless of previous virologic failure with 95% binomial confidence intervals at 48 and 96 weeks. (A) Intention-to-treat analysis. (B) Per protocol analysis. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine

copies/mL. This patient was enrolled before the announcement of the interim analysis of ACTG5202 in March 2008 and achieved an HIV-1 RNA level of <50 copies/mL by the end of that month. One patient in the TDF/FTC arm had a history of lamivudine use. That patient was included in the analysis because this aspect of the medical history was identified after randomization and initiation of the allocated treatment.

Efficacy results

In the primary efficacy analysis, the time to virologic failure was not significantly different in the ABC/3TC arm from that observed in the TDF/FTC arm by 96 weeks (HR, 2.09; 95% CI, 0.72-6.13; p=0.178). Virologic failure occurred in 5 and 10 patients in the ABC/3TC and TDF/FTC arms, respectively (Fig. 2A). In the secondary efficacy analysis, the times to the first occurrence of confirmed virologic failure or discontinuation of the initially allocated regimen were not different between the two arms (HR, 1.30; 95% CI, 0.61-2.77; p=0.502) (Fig. 2B). Among the ITT population, the proportion of patients with an HIV RNA level <50 copies/mL at week 48 regardless of previous virologic failure was 81.5% in the ABC/3TC group and 80% in the TDF/FTC group, for a difference of -1.5% (95% CI, -16% to 13%), and at week 96, 72.2% and 78.2% for the ABC/3TC and TDF/FTC groups, respectively, for a difference of 6% (95% CI, -10% to 22%) (Fig. 3A). The per protocol analysis showed that the proportions at week 48 were 91.7% and 86.3% for the ABC/3TC and TDF/FTC groups, respectively, for a difference of -5.4% (95% CI, -18% to 7%). At week 96, the proportions were 88.6% and 95.6% for the ABC/3TC and TDF/FTC groups, respectively, for a

Figure 4. Safety and tolerability results over 96 weeks. (A) Time to first primary safety endpoint, defined as the first grade 3 or 4 event on the initial randomized regimen, which was at least one grade higher than baseline. (B) Time to tolerability endpoint, defined as the first change in regimen. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine

Table 2. Selected Grade 3 or 4 Events While Receiving Randomized Antiretroviral Drugs

	ABC/3TC (n=54)	TDF/FTC (n=55)	Total (n=109)
Overall, n (%)	13 (24)	10 (18)	23 (21)
Laboratory, n (%)	12 (22)	7 (13)	19 (17)
Alanine aminotransferase, n	0	1	1
LDL-cholesterol, n	6	2	8
Triglycerides, n	0	3	3
Uric acid, n	1	0	1
Serum phosphate, n	2	0	2
Serum calcium, n	1	0	1
Serum creatinine, n	1	0	1
Platelets count, n	1	1	2
Symptoms, n (%)	1 (2)	3 (5)	4 (4)
Depression, n	0	2	2
Fever, n	1	1	2

More than one event occurred in 2 patients.
LDL: low-density lipoprotein

difference of 6.9% (95% CI, -4.2% to 18%) (Fig. 3B). The primary and secondary efficacy analyses did not show a significant difference in viral efficacy between the two arms.

Safety and tolerability results

10 (18.5%) and 7 (12.7%) patients in the ABC/3TC and TDF/FTC groups, respectively, experienced 23 grade 3 or 4 adverse events related to the study drugs while on the initial regimen. The time to the first adverse event was not significantly different between the two arms (HR 0.66; 95% CI, 0.25-1.75, p=0.407) (Fig. 4A). Table 2 shows a list of selected grade 3 or 4 safety events. Among the adverse events, 48% included elevation of lipid markers. The tolerability endpoint, the time to first ART modification, was not significantly different between the two arms (HR 1.03; 95% CI, 0.33-3.19, p=0.964), and only 6 (11.1%) and 6 (10.9%) patients in the ABC/3TC and TDF/FTC arms, respectively,

discontinued the initially allocated regimen by 96 weeks (Fig. 4B). The most common reason for regimen modification was drug toxicity (n=10; 4 in ABC/3TC and 6 in TDF/FTC arm; suspected ABC hypersensitivity reactions based on the appearance of rash and fever in HLA-B*5701-negative patient; n=1, depression; n=3, jaundice; n=3, nausea; n=2, and lipodystrophy; n=1). One patient in the ABC/3TC group developed a cerebral infarction during week 39 but was able to continue the study drugs. No deaths were registered during the study period.

Changes in the CD4 cell count and other parameters of interest

The increase in the median CD4 count from baseline to 48 weeks was marginally larger in the ABC/3TC arm than in the TDF/FTC arm (median: ABC/3TC: 216, TDF/FTC: 192, p=0.107). This difference was significantly larger at 96

Table 3. Median Values of Changes in Parameters of Interest from Baseline to 96 Weeks

	ABC/3TC (n=54)				TDF/FTC (n=55)				
	Number tested (baseline, week 96)	Baseline	Week 96	Median Δ	Number tested (baseline, week 96)	Baseline	Week 96	Median Δ	p value
CD4 cell count (/μL)	54, 43	236.5	545	328	55, 45	269	493	216	0.031
Lipids									
LDL-cholesterol (mg/dL)	54, 16	91.5	149	31.5	53, 16	94	97	2	0.026
Triglyceride (mg/dL)	54, 29	132	257	111	55, 26	114	202	40.5	0.037
Renal tubular markers									
Urinary β2 microglobulin (μg/g Cre)	49, 32	195.8	99.2	-94.9	52, 38	138.4	303.9	86.6	<0.001
Tubular resorption of phosphate (%)	49, 32	93	92	-1.4	50, 36	92	91	-2.6	0.930

LDL: low-density lipoprotein

Figure 5. Changes in the renal function between baseline and 96 weeks. (A) Changes in the estimated glomerular filtration rate calculated with the Modification of Diet in Renal Disease study equation adjusted for the Japanese population. (B) Changes in creatinine clearance calculated with the Cockcroft-Gault equation. The data are presented as the mean±95% confidence interval. ATV/r: ritonavir-boosted atazanavir, ABC/3TC: abacavir/lamivudine, TDF/FTC: tenofovir/emtricitabine

weeks (ABC/3TC: 328, TDF/FTC: 236, p=0.031, Table 3). The increases in both LDL-cholesterol and triglycerides from baseline to 96 weeks were more significant in the ABC/3TC arm than in the TDF/FTC arm. One patient in the TDF/FTC arm had been treated with lipid-lowering medications prior to study enrollment. Furthermore, 7 patients and 1 patient in the ABC/3TC and TDF/FTC arms, respectively, started lipid-lowering agents during the study period. With regard to renal tubular markers, the levels of urinary β2 microglobulin increased in the TDF/FTC arm (median: 86.6 μg/g Cre), whereas it decreased in the ABC/3TC arm (median: -94.9 μg/g Cre). These changes were significantly different between the two arms (p<0.001). On the other hand, tubular resorption of phosphate did not show changes from baseline to 96 weeks in the two groups, and the levels were not different between the two arms (Table 3).

Changes in the renal function

A data analysis using repeated measures mixed models showed a significant decrease in the mean eGFR from baseline to 96 weeks in both groups (ABC/3TC: -8.7 mL/min/1.73 m^2, 95%CI -13.3 to -4.2, p<0.001; TDF/FTC: -9.2 mL/min/1.73 m^2, 95%CI -13.7 to -4.7, p<0.001) (Fig. 5A). There was no significant interaction between the trend of the two arms over time (p=0.202), thus indicating that the

change in eGFR from baseline to 96 weeks was not significantly different between the two arms. A sensitivity analysis of creatinine clearance calculated using the Cockcroft-Gault equation showed that creatinine clearance decreased significantly from the baseline in the TDF/FTC arm (-9.6 mL/min, 95%CI -16.6 to -2.5, p<0.001) but not in the ABC/3TC arm (-4.1 mL/min, 95%CI -11.2 to 3.0, p=0.466)(Fig. 5B). No significant interaction between the trend of the two arms was observed with respect to creatinine clearance (p=0.403). Two patients in the ABC/3TC arm progressed to more advanced chronic kidney disease (CKD) stage by the last per protocol visit: one patient progressed to stage 4 CKD (eGFR <30 mL/min/1.73 m^2) and the other to stage 3 CKD (eGFR <60 mL/min/1.73 m^2). However, ABC/3TC did not appear to be the causative drug for renal dysfunction in these two cases because the deterioration in the renal function was associated with the development of malignant lymphoma in the former patient and with the commencement of fenofibrate treatment in the latter; renal function recovered rapidly in the latter patient after the discontinuation of fenofibrate.

Discussion

Although insufficiently powered to show the noninferiority of the viral efficacy of ABC/3TC relative to TDF/

FTC, this pilot study is the first randomized study conducted in Asia to elucidate the efficacy and safety of fixed doses of these two regimens each administered in combination with ATV/r for initial HIV-1 therapy. Viral efficacy, safety, and tolerability were not significantly different in the two arms of Japanese patients with a baseline HIV viral load <100,000 copies/mL over 96 weeks. Both regimens showed favorable viral efficacy, as in the ITT population, 72.2% and 78.2% of the patients in the ABC/3TC and TDF/FTC arms, respectively, had HIV-1 viral loads of <50 copies/mL at 96 weeks. Both regimens were also well-tolerated, as only 11.1% and 10.9% of the patients in the ABC/3TC and TDF/FTC arms, respectively, discontinued the allocated regimen by 96 weeks. Clinically suspected (not immunologically-confirmed) ABC-associated hypersensitivity reaction occurred in only one (1.9%) patient in the ABC/3TC arm, confirming that ABC hypersensitivity is rare in populations in which HLA-B*5701-positive patients are uncommon. Thus, this trial suggests that ABC/3TC may be an efficacious and safe regimen for use in HLA-B*5701-negative populations, such as the Japanese, with a baseline HIV viral load <100,000 copies/mL.

The usefulness of ABC/3TC has recently received higher recognition for two reasons. One, a meta-analysis by the FDA did not confirm the association between ABC use and myocardial infarction (9). Two, it became clear that TDF-induced renal tubulopathy results in decreased bone mineral density due to phosphate wasting and a decreased renal function, both of which might develop into serious complications with long-term TDF use (12-14, 29, 30). On the other hand, greater deteriorations in the levels of lipid markers were noted in ABC/3TC than in TDF/FTC in clinical trials comparing these two agents (16, 17). The present study also demonstrated that the increases in the LDL-cholesterol and triglyceride levels were higher in the ABC/3TC arm than in the TDF/FTC arm.

TDF-induced nephrotoxicity is of particular interest in this study because a low body weight is an important risk factor, and body stature was much smaller in this study population (median baseline body weight 64 kg), than in the ASSERT study (72 kg), which compared the renal function between patients receiving ABC/3TC and TDF/FTC with efavirenz in Europe (17, 18, 20). This study showed that changes in the renal function from baseline were not significantly different between the two arms, similar to the findings of the ASSERT study. None of the patients in the TDF/FTC arm exhibited progression of CKD stage. On the other hand, the levels of urinary β2 microglobulin deteriorated significantly from baseline in the TDF/FTC arm, whereas improvements were observed in the ABC/3TC arm. This is also similar to the findings reported by the ASSERT trial. This suggests that urinary β2 microglobulin is a more sensitive marker for evaluating TDF nephrotoxicity than the renal function calculated by serum creatinine, as also demonstrated in our previous work (31). Tubular resorption of phosphate, another marker examined to evaluate the renal

tubular function, did not exhibit any changes from baseline or between the two arms, suggesting that urinary β2 microglobulin may be a better marker for evaluating TDF nephrotoxicity than tubular resorption of phosphate. Of note, in both arms, the renal function did significantly decrease from baseline. To our knowledge, this is the first randomized trial comparing ABC/3TC and TDF/FTC that observed deterioration of the renal function after the initiation of ART. This result highlights the importance of regular monitoring of renal function after initiation of ART, although it is difficult to draw a firm conclusion on the prognosis of the renal function from this study, due to the limited length of the observation period and the small number of enrolled patients.

Only one patient (1.9%) in the ABC/3TC arm developed a clinically suspected ABC-associated hypersensitivity reaction, which was diagnosed based on the appearance of a skin rash and fever six weeks after commencement of the study drug. The patient fully recovered after discontinuation of the drugs. The ASSERT trial of HLA-B*5701-negative patients reported a similar incidence (3%) of clinically suspected ABC hypersensitivity reactions (17). The one case observed in our trial could be a false positive, because ABC hypersensitivity reactions commonly occur 9-11 days after the initiation of therapy (32), and ABC hypersensitivity was not confirmed immunologically. Nonetheless, immediate discontinuation of ABC is highly recommended even in HLA-B*5701-negative patients suspected of ABC hypersensitivity, since ABC hypersensitivity can occur in such patients (33) and errors in genotyping for HLA or reporting a genotype might occur in practice (34).

Several limitations of this trial should be acknowledged. First, due to the shortage of enrolled patients, the trial was insufficiently powered to test non-inferiority of the viral efficacy of ABC/3TC against TDF/FTC, as initially planned. However, the safety and tolerability data of these regimens in Asia are a valuable asset for patients from this region, and efficacy data could be utilized as part of a meta-analysis in the future. Second, the enrolled subjects were mostly men (primarily men who had sex with men and very few injection drug users). Further studies are needed to examine the efficacy and safety of these regimens in women and patients with different routes of transmissions in Asia.

In summary, this randomized trial demonstrated high efficacy and safety of fixed-dose ABC/3TC and TDF/FTC in combination with ATV/r over 96 weeks for treatment-naïve Japanese patients with a baseline HIV-1 viral load <100,000 copies/mL, although it was insufficiently powered to show non-inferiority of the viral efficacy of ABC/3TC compared with TDF/FTC. ABC/3TC with ATV/r is a safe and efficacious initial regimen for treating HLA-B*5701-negative patients with a baseline HIV-1 viral load <100,000 copies/mL.

Authors' contributions

Acknowledgement

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [http : / / www. aidsinfo. nih. gov / contentfiles / lvguidelines / adultandadolescentgl.pdf].
2. European AIDS Clinical Society Guidelines version 6 [http://www.europeanaidsclinicalsociety. org / images / stories / EACS-Pdf / EACSGuidelines-v6.0-English.pdf].
3. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361: 2230-2240, 2009.
4. Smith KY, Patel P, Fine D, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23: 1547-1556, 2009.
5. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 23: 1603-1614, 2001.
6. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358: 568-579, 2008.
7. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 9: 207-214, 2008.
8. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426, 2008.
9. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 61: 441-447, 2012.
10. Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr 35: 269-273, 2004.
11. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 40: 1331-1333, 2002.
12. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 22: 2155-2163, 2008.
13. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 51: 496-505, 2010.
14. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis 203: 1791-1801, 2011.
15. Guidelines for antiretroviral therapy. Japanese Ministry of Health and Welfare, in Japanese. [http://www.haart-support.jp/pdf/guideline2012.pdf].
16. Sax PE, Tierney C, Collier AC, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 204: 1191-1201, 2011.
17. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 55: 49-57, 2010.
18. Nishijima T, Gatanaga H, Komatsu H, et al. Renal function de-

clines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. PLoS One 7: e29977, 2012.

19. Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res 8: 504-509, 2010.

20. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 21: 1273-1281, 2007.

21. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One 6: e22661, 2011.

22. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340: c869, 2010.

23. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents October 10, 2006. [http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000629.pdf].

24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41, 1976.

25. Hattori J, Shiino T, Gatanaga H, et al. Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan. Antiviral Res 88: 72-79, 2010.

26. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis 48: e108-e116, 2009.

27. DIVISION OF AIDS TABLE FOR GRADING THE SEVERITY OF ADULT AND PEDIATRIC ADVERSE EVENTS VERSION 1.0, DECEMBER, 2004; CLARIFICATION AUGUST 2009. [http://www.mtnstopshiv.org/sites/default/files/attachments/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf].

28. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53: 982-992, 2009.

29. Kudo K, Konta T, Mashima Y, et al. The association between renal tubular damage and rapid renal deterioration in the Japanese population: the Takahata study. Clin Exp Nephrol 15: 235-241, 2011.

30. Ando M, Yanagisawa N, Ajisawa A, Tsuchiya K, Nitta K. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transplant 26: 3224-3229, 2011.

31. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary β_2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 22: 744-748, 2006.

32. Phillips EJ. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Clin Infect Dis 43: 103-105, 2006.

33. Sun HY, Hung CC, Lin PH, et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 60: 599-604, 2007.

34. Martin MA, Klein TE, Dong BJ, Pirmohamed M, Haas DW, Kroetz DL. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther 91: 734-738, 2012.

Prophylactic Effect of Antiretroviral Therapy on Hepatitis B Virus Infection

Hiroyuki Gatanaga,[1,2] Tsunefusa Hayashida,[1,2] Junko Tanuma,[1] and Shinichi Oka[1,2]

[1]AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, and [2]Center for AIDS Research, Kumamoto University, Japan

Background. Hepatitis B virus (HBV) infection is common in individuals infected with human immunodeficiency virus, especially in men who have sex with men (MSM). Almost all currently used regimens of antiretroviral therapy (ART) contain lamivudine (LAM) or tenofovir disoproxil fumarate (TDF), both of which have significant anti-HBV activity. However, the prophylactic effect of ART on HBV infection has not been assessed previously.

Methods. Non-HBV-vaccinated HIV-infected MSM were serologically evaluated for HBV infection using stocked serum samples. Cases negative for HBV surface antigen (HBsAg), antibody to HBsAg (anti-HBs), and antibody to HBV core antigen (anti-HBc) in first serum samples were serologically followed until last available stocked samples. HBV genotype and LAM-resistant mutation (rtM204V/I) were analyzed in cases that became HBsAg-positive.

Results. The first stocked samples were negative for all analyzed HBV serological markers in 354 of 1434 evaluated patients. The analysis of their last samples indicated HBV incident infection in 43 of them during the follow-up period. The rate of incident infections was lower during LAM- or TDF-containing ART (0.669 incident infections in 100 person-years) than during no ART period (6.726 incident infections in 100 person-years) and other ART (5.263 incident infections in 100 person-years) ($P < .001$). Genotype A was most prevalent (76.5%), and LAM-resistant HBV was more frequent in incident infections during LAM-containing ART (50.0%) than in those during no ART and other ART (7.1%) ($P = .029$).

Conclusions. LAM- and TDF-containing ART regimens seem to provide prophylaxis against HBV infection, although drug-resistant strains seem to evade these effects.

Keywords. lamivudine; tenofovir disoproxil fumarate; resistant; chronic infection.

Patients with human immunodeficiency virus (HIV) infection are at high risk for both hepatitis B virus (HBV) infection and development of chronic infection [1–4]. Based on information from Western countries, the rate of coinfection varies according to risk categories; the highest rate is in men who have sex with men (MSM), with a slightly lower rate among intravenous drug users, and much lower in individuals infected through heterosexual contacts [5–8]. In Japan, HIV/

HBV coinfection is also significantly associated with MSM [9, 10]. The progression of chronic HBV infection to cirrhosis, end-stage liver diseases, and/or hepatocellular carcinoma is more rapid in HIV-infected persons than in those with chronic HBV infection alone [11, 12]. Vaccination of non-HBV-immunized HIV-infected individuals is recommended to prevent HBV infection [13]. However, all current recommended antiretroviral therapy (ART) regimens contain lamivudine (LAM) or tenofovir disoproxil fumarate (TDF), both of which have significant anti-HBV activity [14]. Do these ART regimens provide any prophylaxis against HBV infection? This is an important question, as a positive answer could influence the strategy applied to prevent HBV infection in HIV-infected individuals. To delineate the hepatitis B prophylactic effect of ART, we used stocked samples for serological evaluation of HBV infection in HIV-infected MSM. The present